Adamas Pharmaceuticals, Inc.

MediWound priced an underwritten public offering of 4.4 million shares at $5 apiece.

The Emeryville, Calif.-based firm secures FDA approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients.

Hurricane Harvey was upgraded to a category 2 storm overnight and could be a category 3 before the day is over.

Biogen's new spine disease drug outperformed expectations during its commercial debut.

Insiders at these companies are scooping up shares of their own stock lately.

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a weak on high relative volume candidate

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a weak on high relative volume candidate

Looking at this list, you realize things turned out to be a lot better than many of the bears had feared, Cramer says.

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a strong on high relative volume candidate

James 'Rev Shark' DePorre shares his views on starting fresh in 2016 and the end of the year. Solar3D, Weight Watchers International, Facebook and Amazon.com are among the stocks discussed.

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a strong on high relative volume candidate

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a weak on high relative volume candidate

Trade-Ideas LLC identified Adamas Pharmaceuticals (ADMS) as a strong on high relative volume candidate

These stocks rising on unusual volume are within range of triggering breakout trades.

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.

Winning FDA approval isn't always a win.

The experiences of three biotechs show how drug approvals don't always translate into stock gains.

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.

These companies will do well, despite a range bound sector.

This sector is one of the few areas of the market where you'll find myriad compelling values.

The retailer is struggling to combat a growing issue.

Global travel agency platform files for bankruptcy facing industry headwinds.

TikTok's future in the United States depends entirely on the incoming president's support. President-elect Trump will be pushing for investors to see his show.